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Modifiable patient factors are associated with
reverse vein graft occlusion in the era of duplex
scan surveillance
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Objective: Modifiable patient factors that contribute to graft occlusion may be addressed after surgery. To determine risk
factors associated with reverse vein graft (RVG) occlusion, we examined the characteristics and duplex scan surveillance
(DS) patterns of patients with RVGs.
Methods: Patients treated with RVG from January 1996 through December 2000 were identified from a prospective
registry. The study population consisted of all patients with RVGs performed during the study period with grafts that
subsequently occluded. Patients whose grafts remained patent served as age-matched and gender-matched control
subjects. The prescribed DS regimen was every 3 months for the first postoperative year and every 6 months thereafter.
Early DS failure was defined as having no DS within the first 3 months. Cox proportional hazards analysis was used to
compare the two groups. Hazard ratios were calculated.
Results: During the study period, 674 patients underwent RVG. Fifty-five patients with occluded RVGs were compared
with 118 with patent RVGs. The follow-up period for occluded grafts was 13.40  12.59 months and for patent grafts
was 32.40  15.61 months. Dialysis therapy, a known hypercoagulable state, continued smoking, and DS failure were
independent factors associated with RVG occlusion. The hazards ratio for dialysis was 6.45 (95% CI, 3.07 to 13.51; P <
.001), for current smoking was 4.72 (95% CI, 2.5 to 8.85; P < .001), for hypercoagulable state was 2.99 (95% CI, 1.47
to 6.10; P  .003), and for early DS failure was 2.43 (95% CI, 1.29 to 4.59; P  .006).
Conclusion: Continued smoking and failure to undergo DS within the first three postoperative months are modifiable
factors associated with RVG occlusion. Smoking cessation and graft surveillance must be stressed to optimize patency of
infrainguinal RVGs. (J Vasc Surg 2003;37:47-53.)
Infrainguinal bypass graft occlusion occurs in 10% to
30% of grafts.1-5 As the population ages, the number of
infrainguinal reconstructions continues to increase. There-
fore, all surgeons performing reconstruction for limb isch-
emia will encounter more patients needing and having had
leg bypass grafts. The patency rate for repeat leg bypass
grafting ranges from 20% to 57% at 5 years.6-9 The ampu-
tation rate after reverse vein graft (RVG) occlusion is
10%.10 In our experience, revision of stenosis detected with
duplex scan results in a 5-year assisted primary patency rate
of 92%.11 The importance of detection and correction of
graft-threatening lesions to prevent graft occlusion is there-
fore obvious.2,11,12
Data strongly suggest that routine duplex scan surveil-
lance (DS) and correction of stenosis throughout the post-
operative period improve graft patency.4,11-13 Vein graft
stenosis often precedes graft occlusion. Routine DS can
effectively detect these lesions before occlusion. Sixty-nine
percent of vein graft abnormalities are detected in the first 6
months, but abnormalities can develop at any time during
the postoperative period.14 Therefore, the policy at our
institution has been continued DS for the life of the graft.
Postoperative DS and revision of detected lesions has been
shown to be cost effective when compared with the treat-
ment of graft occlusion.15,16
Multiple reports have examined the various factors that
affect the outcome of infrainguinal bypass grafts. These
reports have largely focused on anatomic considerations,
end-stage renal disease, hypercoagulable states, gender,
choice of conduit, and diabetes mellitus.17-21 The goal of
this report was to determine the causes of RVG occlusion
that can be addressed during the postoperative period,
specifically factors that are within patient and physician
control.
METHODS
Patient characteristics. Patients treated with infrain-
guinal RVG from January 1996 through December 2000
at Oregon Health & Science University and the Portland
Veterans Affairs Medical Center were identified from pro-
spectively maintained registries. Patients who underwent
RVG during the study period with grafts that later occluded
constituted the study group. An age-matched and gender-
matched control group twice the size of the study group
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with grafts that remained patent was chosen. Data ab-
stracted from the medical record included smoking status,
medical history, DS pattern, time to graft occlusion, oper-
ative indication, previous ipsilateral leg bypass, previous
inflow procedure, previous graft revision, type of vein graft,
site of distal anastomosis, and survival. Patients were ex-
cluded if no follow-up information was available or if the
RVG occluded before hospital discharge. If a patient had
multiple RVGs, only the first graft was considered.
Survival data were obtained from the medical record
when available or the Social Security Death Index web-
site.22 Information from the Social Security Death Index
website was considered valid if there was an exact match of
first and last name and social security number.
The prescribed postoperative DS regimen was every 3
months for the first year, with the initial DS examination
completed before hospital discharge and every 6 months
thereafter. Early DS failure was defined as no DS within the
first 3 months. Patients with graft occlusion before the first
scheduled duplex scan examination were not considered to
have DS failures. Late DS failure was defined as patients
who underwent DS within the first 3 months but then
failed to have DS from 6 to 12 months in the first postop-
erative year.
Current smoking was considered any cigarette smoking
during the postoperative period. A patient was considered
to have a hypercoagulable state if there was a documented
diagnosis of antiphospholipid antibody, factor V Leiden,
prothrombin gene mutation, antithrombin III deficiency,
or protein C or S deficiency in the medical record. Only
patients with more than one episode of graft thrombosis
were routinely tested for a hypercoagulable state. All pa-
tients with a documented hypercoagulable state were
treated with warfarin, except one patient who had a hetero-
zygote factor V Leiden and had repeated gastrointestinal
bleeding.
Criteria for patency and occlusion were those suggested
by Rutherford et al.23 Graft occlusion was detected with
physical examination or DS or both and then confirmed
with angiography.
Statistical analysis. A Cox proportional hazards
model was used to compare patients with occluded grafts
with those with patent grafts. The variables included in the
model were known risk factors for graft occlusion and the
progression of arteriosclerosis (Table I). Hazard ratios for
graft occlusion with 95% CIs were calculated for each
variable. To compare the effects of the patient factors on
patency, adjusted patency curves were calculated with the
Cox regression model. These curves were statistically ad-
justed to control for the covariates in the model (Table I)
and isolate the effect of the desired variable on graft pa-
tency. These curves are not univariate life-tables but are a
form of multivariate analysis.
Spearman correlation coefficients were calculated to
evaluate the association between early DS failure and other
markers of noncompliance. The markers of noncompliance
used were failure to attend regular clinic appointments or
failure to adhere to the prescribed DS regimen throughout
the follow-up period. Correlation coefficients were also
calculated for other patient factors, such as medical comor-
bidities and distance from the institution, which were hy-
pothesized to have an association with noncompliance.
RESULTS
Patient characteristics. From January 1996 to De-
cember 2000, 674 patients underwent RVG. Fifty-five
patients, 20% of whose grafts had been revised before
occlusion (n  11), had a graft occlusion and constituted
the study group. One hundred eighteen patients, 31% of
whose grafts had been revised during the follow-up period
(n  36), matched for age and gender with patent grafts
served as controls. The patient characteristics are listed in
Table II.
Factors associated with graft occlusion during fol-
low-up period. The factors evaluated in the model that
were not significantly associated with graft occlusion in-
cluded hypertension, diabetes, atrial fibrillation, hyperlip-
idemia, aspirin therapy, prior ipsilateral leg bypass or inflow
procedure, operative indication, below-knee distal anasto-
mosis, late DS failure, and use of arm vein (data not shown).
Prior graft revision was associated with a decreased risk of
occlusion (hazards ratio, 0.55; P  .09). Dialysis therapy,
continued smoking, presence of a known hypercoagulable
state, and early DS failure were significant independent risk
factors for graft occlusion. The hazard ratios of those
factors associated with occlusion are listed in Table III.
Effect of independent risk factors on graft patency.
The mean time to occlusion was 13.4 12.6 months (n
55). The mean follow-up period for patent grafts was
32.4  15.6 months (n  118). With the Cox regression
model, the effect of the independent variables on time to
occlusion was evaluated. The adjusted patency curves are
shown in Figs 1 to 4. Assisted primary patency rates were
significantly lower for patients currently smoking than non-
Table I. Factors analyzed in Cox proportional hazards
model
Variable
Age
Rest pain or ulceration
Gender
Aspirin therapy
Current smoking
Known hypercoagulable state
Diabetes
Atrial fibrillation
Hyperlipidemia
Dialysis
Prior inflow procedure
Hypertension
Late DS failure
Early DS failure
Prior revision
Previous ipsilateral bypass
Below-knee graft
Saphenous vein graft
Arm vein graft
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smoking, for those on dialysis therapy compared with no
dialysis, for those with early DS failure compared with
compliant DS, and for those with a known hypercoagulable
state compared with those without a known hypercoagula-
ble state.
Factors associated with noncompliance. Early DS
failure was associated with failure to comply with regular
clinic visits and regular DS examinations throughout the
duration of the postoperative period. No association was
seen between these markers of compliance and cigarette
smoking, driving distance to the institution, diabetes mel-
litus, prior ipsilateral bypass, dialysis, gender, or age. The
correlation coefficients are listed in Table IV.
DISCUSSION
The goal of this report was to identify patient factors
that contribute to RVG occlusion that can be addressed
and potentially modified during the postoperative period.
In this group of patients, continued smoking and failure to
participate in DS during the first 3 postoperative months
were identified as modifiable patient factors associated with
RVG occlusion.
Failure to undergo early DS was associated with an
increased risk of graft occlusion. The logical assumption is
that early DS detects graft-threatening lesions that are then
revised, thus preventing graft occlusion. In this report,
patients who had undergone graft revision were half as
likely to have an occlusion during the follow-up period as
patients without revision (P  .09). Although this did not
reach statistical significance, the trend was strong. Probably
this represents a statistical type II error resulting from a
small sample size (n 47 revisions). It has been established
at this institution and others that detection of stenosis with
DS and subsequent revision improves graft paten-
cy.4,11,13,14
Early DS failure was an independent risk factor associ-
ated with graft occlusion; however, late DS failure was not
significantly associated with occlusion in patients participat-
ing in early DS. Other authors have suggested that almost
all vein graft lesions are detectable in the early postoperative
period and that less intensive surveillance may be justified if
early studies do not reveal an abnormality.24,25 Previous
studies from our institution have found that 69% of steno-
ses detected and subsequently revised are detected in the
first 6 months and 17% are detected from 9 to 12 months.13
Routine DS can only improve patency if patients are
compliant with the prescribed regimen. In this report, an
association was found between early DS failure and failure
Table II. Characteristics of patients with occluded grafts (study group) compared with patients with patent grafts
(control group)
Patient characteristics Occluded grafts Patent grafts P value*
Mean age (y) 67.4 67.3 .95
Male gender 84% (46) 93% (110) .3
Rest pain or ulceration 96% (53) 94% (111) .5
Prior ipsilateral bypass 24% (13) 19% (22) .3
Below-knee anastomosis 93% (51) 88% (104) .3
Prior revision 20% (11) 31% (37) .1
Current smoking 60% (33) 30% (35) .001
Aspirin therapy 78% (43) 77% (91) .88
Known hypercoagulable state 18% (10) 8% (9) .04
Diabetes mellitus 55% (30) 53% (63) .81
Atrial fibrillation 18% (10) 19% (22) .84
Dialysis therapy 18% (10) 3% (4) .001
Warfarin therapy 44% (24) 27% (32) .04
Hyperlipidemia 40% (22) 36% (42) .58
Prior inflow procedure 47% (26) 37% (44) .22
Hypertension 89% (49) 81% (96) .17
Early DS failure 25% (14) 11% (13) .01
Arm vein 15% (8) 5% (6) .07
Late DS failure 20% (11) 14% (17) .31
*P value calculated with independent sample two-tailed t test.
Table III. Hazards ratios for graft occlusion calculated with Cox proportional hazards model
Patient factor
No. of
patients Hazards ratio 95% CI P value
Dialysis 14 6.45 3.07-13.51 .001
Current smoking 68 4.72 2.50-8.85 .001
Known hypercoagulable state 19 2.99 1.47-6.10 .003
Early DS failure 27 2.43 1.29-4.59 .006
Revision 47 0.55 0.27-1.09 .088
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to participate in regular follow-up for the duration of the
postoperative period. Because a significant correlation was
seen between early DS failure and failure to participate in
regular follow-up, we can conclude that early DS failure is a
marker for poor compliance throughout the postoperative
period. This association potentially explains the decreased
RVG patency out to 48 months.
Failure to undergo DS in the first 3 postoperative
months is a combination of system and patient failure. The
results of this study confirm the importance of early DS
examinations. Other investigators have found that intraop-
erative duplex scan and revision reduces early graft fail-
ure.26 Ten percent of the RVGs were immediately revised
on the basis of abnormal intraoperative DS findings. Intra-
operative DS after RVG would reduce the incidence rate of
early DS failure. However, to date, this has not been done
at our institution.
One hypothesis was that older patients with multiple
medical problems would be less likely to participate in
routine follow-up. In this series, failure to participate in
routine follow-up was independent of patient comorbidi-
ties. No significant association was seen between failure of
Fig 1. Adjusted assisted primary patency curve of RVGs comparing patients currently smoking (n  68) with
nonsmoking patients (n  105). Curve was generated with Cox proportional hazard model. P  .001.
Fig 2. Adjusted assisted primary patency curve of RVGs comparing patients who fail early DS (n 27) with compliant
patients (n  146). Curve was generated with Cox proportional hazard model. P  .006.
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3-month DS and cigarette smoking, dialysis, prior ipsilat-
eral bypass, diabetes mellitus, gender, driving distance to
the hospital, or age. In this study, these issues did not
influence a patient’s ability to participate in routine fol-
low-up or DS. Other issues that might influence patient
compliance with follow-up are terminal illness, cultural
barriers, or lack of transportation to the clinic. These issues
are beyond the scope of this analysis but should be evalu-
ated in future studies.
The association between decreased graft patency and
cigarette smoking has been previously established.27,28
Greenhalgh et al27 prospectively followed patients with
aortoiliac reconstruction and RVG and serially measured
serum markers for tobacco use. The patients with oc-
cluded grafts had significantly elevated blood levels of
carboxyhemoglobin. Similarly, Wiseman et al28 mea-
sured serum smoking markers in patients with occluded
and patent vein grafts. These authors found that the
Fig 3. Adjusted assisted primary patency curve of RVGs comparing patients with end-stage renal disease (n 14) with
patients with normal renal function (n  159). Curve was generated with Cox proportional hazard model. P  .001.
Fig 4. Adjusted assisted primary patency curve of RVGs comparing patients with known hypercoagulable state (n 
19) with patients without known hypercoagulable state (n 154). Curve was generated with Cox proportional hazard
model. P  .003.
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patients with occluded grafts had significantly elevated
levels of smoking markers compared with those with
patent grafts. Patency was significantly higher in non-
smoking patients when compared with patients who
smoked (84% versus 63%; P  .02). Other investigators
have shown an association between cigarette smoking
and the development of graft stenosis.29 In our report,
continued smoking had a profound effect on graft pa-
tency. This information shows the importance of contin-
ued patient education about smoking cessation.
The use of aspirin was not associated with a decreased
risk of graft occlusion in the regression model. Multiple
previous studies, including two metaanalyses, have shown
that antiplatelet therapy reduces the incidence rate of graft
occlusion.30,31 However, most patients in this report were
taking aspirin. Most of those not using aspirin were taking
warfarin, which was initiated for a prior graft occlusion,
hypercoagulable state, or atrial fibrillation. Because such a
large percentage of the patients in both groups were taking
aspirin or were undergoing anticoagulation, a larger sample
size would be necessary to show an independent effect of
aspirin on graft patency.
In conclusion, this study emphasizes the importance of
routine DS and smoking cessation. Patients with failure for
early DS and who continue to smoke cigarettes are more
likely to have graft occlusion. Smoking cessation and ad-
herence to postoperative DS must be stressed to optimize
graft patency.
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DISCUSSION
Dr Alun H. Davies (London, United Kingdom). Can I ask
you two questions? One, you have presented us with patency data,
but surely the main aim of surveillance is actually with respect to
limb salvage. So, do you have any data on your limb salvage rather
than patency rates, is my first question.
And the second question is, you have started your surveillance
program at 3 months, whereas several other people would believe
in actually starting it at 1 week, 6 sweeks, and then 3 months.
Dr Mary E. Giswold. To address the first question, we did
not look at limb salvage in this paper. So, although it is a good
question, I do not have that information.
Initally, from 1996 to 1997, patients did not routinely un-
dergo duplex prior to discharge. The current duplex surveillance
policy at Oregon Health & Sciences consists of a duplex exam prior
to discharge from the hospital, every 3 months for the first post-
operative year, and then every 6 months thereafter. The results of
this study demonstrate the importance of early duplex surveillance.
Dr George Andros (Los Angeles, Calif). You defined these
variables as modifiable, but are they really? Perhaps in the next 2
years you will institute an education program to modify these
variables and teach patients to attend the clinic and not to smoke.
At that time, maybe you will let us know how well education serves
to modify adverse variables.
Dr Giswold. In the vascular clinic at OHSU, smoking cessa-
tion is discussed at every visit. Patients are reminded in a construc-
tive supportive manner about the importance of smoking cessa-
tion. We also routinely discuss aspirin therapy and compliance with
duplex surveillance. These discussions are documented in the clinic
note for each visit.
Dr Thomas Holzenbein (Vienna, Austria). One of your
modifiable risk factors was aspirin therapy. How do you monitor
aspirin therapy? Or did you use Coumadin in any of these patients?
Dr Giswold. About 80% of the patients were on aspirin. This
is based on information available in the clinic chart. Most of the
patients that were not on aspirin were actually on Coumadin for
either atrial fibrillation or a hypercoagulable state.
Dr Mark Nehler (Denver, Colo). The take-home message of
your paper is that noncompliant patients get poor results for graft
surveillance. We have actually used this as criteria, not in isolation,
but with other factors—substantial foot necrosis and/or alternate
conduit. To not offer limb salvage attempts in historically noncom-
pliant patients because if they do not comply with the graft
surveillance program limb salvage is often not going to be success-
ful. Do you have any comment?
Dr Giswold. At OHSU, we do not consider socioeconomic
status when operating for limb salvage. When this situation does
arise, compliance can be optimized by duplexing the graft prior to
the patient’s discharge from the hospital.
Dr William D. Turnipseed (Madison, Wis). I am interested
in looking at the 55 graft failures and the time interval at which
they occurred. Did they all occur within that 3-month or 6-month
period between failed visits? Are you culling out the technical
errors to begin with, or do you think patient compliance alone is an
important factor in keeping these grafts open?
Dr Giswold. The mean time to graft occlusion was 13
months. The mean time to occlusion for the patients who failed to
have a duplex exam in the first 3 months was 8 months. Patients
with grafts that occluded prior to discharge were excluded. There-
fore, many of the patients whose grafts occluded because of a
technical error were excluded. So, I think that the effect of the
duplex exam and then having a subsequent revision is real.
Dr G. Patrick Clagett (Dallas, Tex). Would you care to
speculate on the mechanism of occlusion among the smokers? It
would seem to me that you might have some information with
regard to whether they more prone to intimal hyperplastic events,
or is it perhaps some ill-defined hypercoagulable influence that
leads to occlusion among smokers?
Dr Giswold. The time to occlusion for the patients smoking
cigarettes was 14 12 months. The time to occlusion for patients
who were not smoking was 31 16 months. This was significantly
different, with a P value of less than .001. This difference could be
attributed to accelerated neointimal hyperplasia or arteriosclerosis.
There were more patients who occluded sooner in the group of
patients who continued smoking; potentially these patients had a
degree of hypercoagulability related to smoking.
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